|
Jun 30
|
AbbVie to buy Capstan for up to $2.1 billion in immunology push
|
|
Jun 27
|
FDA approves label updates for BMS’ CAR T cell therapies
|
|
Jun 27
|
Sickle Cell Disease Treatment Market Analysis and Forecast, 2025-2035 | Intensifying Competition as Key Players Advance Gene and Novel Therapies
|
|
Jun 27
|
U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels
|
|
Jun 26
|
Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role?
|
|
Jun 26
|
Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?
|
|
Jun 26
|
Incyte replaces CEO Hoppenot with dealmaker Meury
|
|
Jun 25
|
Cantor Maintains PriceTarget on BMY, Eyes Alzheimer’s Trial as Key Catalyst
|
|
Jun 25
|
Will New Drugs Enable BMY to Offset the Impact of Generic Competition?
|
|
Jun 25
|
3 Top Dividend Stocks to Maximize Your Retirement Income
|
|
Jun 20
|
Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?
|
|
Jun 19
|
Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?
|
|
Jun 19
|
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
|
|
Jun 19
|
Q1 Rundown: Royalty Pharma (NASDAQ:RPRX) Vs Other Branded Pharmaceuticals Stocks
|
|
Jun 18
|
Bristol-Myers Squibb (NYSE:BMY) Declares US$0.62 Common and US$0.50 Preferred Dividends
|
|
Jun 17
|
Bristol Myers Squibb Announces Dividend
|
|
Jun 17
|
Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly
|
|
Jun 17
|
Bristol Myers Squibb Presents Promising Blood Cancer Drug Data at EHA Congress
|
|
Jun 16
|
Bristol Myers Squibb (BMY) Stock Drops Despite Market Gains: Important Facts to Note
|
|
Jun 16
|
Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)
|